Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021)
Scope of the Report
The report titled “Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021)” provides a detailed analysis of the myasthenia gravis market with description of market size and growth. The analysis includes market size in terms of value, and market share on the basis of therapy, by cases and by severity.
The report also provides a brief regional analysis of the US. The analysis includes market size in terms of number of patients on the basis of types of myasthenia gravis. Geographically, the Americas were the largest market and is expected to dominate the market in the forecasted period also. The growth in the market is estimated on the back of rising elderly population in the region.
Furthermore, the report also assesses the key opportunities available in the market and outlines the market dynamics that are and will be accountable for growth of the industry. Growth of the global myasthenia gravis market has also been forecasted for the period 2017-2021, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Some of the prominent players of the market include Avadel Pharmaceuticals, Hoffmann-La Roche, Pfizer, and Argenx. A brief company profiling of these major players have also been provided in the report on the basis of aspects like business overview, financial overview and business strategies adopted by respective companies.
Company Coverage
The US
Executive Summary
Myasthenia gravis is a chronic neuromuscular disease that leads to weakness in the skeletal muscles, which help in the breathing and movement of the body parts including the arms and legs. The word ‘myasthenia gravis’ has Latin and Greek origin and means serious muscle weakness. Myasthenia Gravis is rare and only affects 14 to 20 people out of every 100,000. The main symptom of myasthenia gravis is weakness in the voluntary skeletal muscles, which are muscles under one’s control. Weakness associated with MG typically gets worse with more activity and improves with rest.
The disease is categorized into six types namely: Early-Onset MG, Late-Onset MG, Thymoma-Associated MG, MG with Anti-Musk Antibodies, Ocular MG, and MG with no detectable AChR and MuSK Antibodies. Myasthenia gravis is caused by an error in the transmission of nerve impulses to muscles. Major treatments available for MG are Symptomatic Treatment, Rapid Short-Term Immune-Modulating Treatment, Chronic Long-Term Immune-Modulating Treatment and Surgery.
The global myasthenia gravis market has increased over the past few years and projections are made that the market would rise in the forecasted period i.e. 2017 to 2021 at a significant growth rate. The global myasthenia gravis market is expected to boost by the major factors such as rising geriatric population, technological advancements, approval of monoclonal antibodies, strategies such as mergers and acquisitions etc. Yet the market growth is restrain by some challenges such as competition from off-label drugs, limited availability of FDA approved drugs, high cost of the treatment etc.
The report titled “Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021)” provides a detailed analysis of the myasthenia gravis market with description of market size and growth. The analysis includes market size in terms of value, and market share on the basis of therapy, by cases and by severity.
The report also provides a brief regional analysis of the US. The analysis includes market size in terms of number of patients on the basis of types of myasthenia gravis. Geographically, the Americas were the largest market and is expected to dominate the market in the forecasted period also. The growth in the market is estimated on the back of rising elderly population in the region.
Furthermore, the report also assesses the key opportunities available in the market and outlines the market dynamics that are and will be accountable for growth of the industry. Growth of the global myasthenia gravis market has also been forecasted for the period 2017-2021, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Some of the prominent players of the market include Avadel Pharmaceuticals, Hoffmann-La Roche, Pfizer, and Argenx. A brief company profiling of these major players have also been provided in the report on the basis of aspects like business overview, financial overview and business strategies adopted by respective companies.
Company Coverage
- Avadel Pharmaceuticals
- F. Hoffmann-La Roche
- Pfizer
- Argenx
The US
Executive Summary
Myasthenia gravis is a chronic neuromuscular disease that leads to weakness in the skeletal muscles, which help in the breathing and movement of the body parts including the arms and legs. The word ‘myasthenia gravis’ has Latin and Greek origin and means serious muscle weakness. Myasthenia Gravis is rare and only affects 14 to 20 people out of every 100,000. The main symptom of myasthenia gravis is weakness in the voluntary skeletal muscles, which are muscles under one’s control. Weakness associated with MG typically gets worse with more activity and improves with rest.
The disease is categorized into six types namely: Early-Onset MG, Late-Onset MG, Thymoma-Associated MG, MG with Anti-Musk Antibodies, Ocular MG, and MG with no detectable AChR and MuSK Antibodies. Myasthenia gravis is caused by an error in the transmission of nerve impulses to muscles. Major treatments available for MG are Symptomatic Treatment, Rapid Short-Term Immune-Modulating Treatment, Chronic Long-Term Immune-Modulating Treatment and Surgery.
The global myasthenia gravis market has increased over the past few years and projections are made that the market would rise in the forecasted period i.e. 2017 to 2021 at a significant growth rate. The global myasthenia gravis market is expected to boost by the major factors such as rising geriatric population, technological advancements, approval of monoclonal antibodies, strategies such as mergers and acquisitions etc. Yet the market growth is restrain by some challenges such as competition from off-label drugs, limited availability of FDA approved drugs, high cost of the treatment etc.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Overview of Myasthenia Gravis
2.1.1 Myasthenia Gravis Statistics
2.1.2 Myasthenia Gravis Classification
2.1.3 Symptoms of Myasthenia Gravis
2.1.4 Causes of Myasthenia Gravis
2.1.5 Treatment Types for Myasthenia Gravis
3. GLOBAL MARKET ANALYSIS
3.1 Global Myasthenia Gravis Market Analysis
3.1.1 Global Myasthenia Gravis Drugs Market by Value
3.1.2 Global Myasthenia Gravis Market by Therapy
Anticholinesterase inhibitors
Immunosuppressants
Intravenous Immune Globulins
3.1.3 Global Myasthenia Gravis Market by Cases
Peripheral muscles
Ocular Muscles
Bulbar Muscles
3.1.4 Global Myasthenia Gravis Cases by Severity
4. REGIONAL ANALYSIS
4.1 The US Myasthenia Gravis Market Analysis
4.1.1 The US Myasthenia Gravis Market by Total Patient Volume
4.1.2 The US Myasthenia Gravis Market by 2nd Line Patient Volume
4.1.3 The US Myasthenia Gravis Market by 3rd Line Severe Chronic Refractory Patient Volume
4.1.4 The US Myasthenia Gravis Market by Crisis Patient Volume
5. MARKET DYNAMICS
5.1 Growth Drivers
5.1.1 Rising Prevalence of Disease
5.1.2 Technological Advancements
5.1.3 Rising Geriatric Population
5.2 Challenges
5.2.1 Competition from Off-Label Drugs
5.2.2 Limited Availability of FDA Approved Drugs
5.2.3 High Cost
5.3 Market Trends
5.3.1 Emergence of New Entrants
5.3.2 Growing Number of Mergers and Acquisitions
5.3.3 Approval of Novel Monoclonal Antibodies
6. COMPETITIVE LANDSCAPE
6.1 The US Myasthenia Gravis Market Players by Product Comparison
7. COMPANY PROFILING
7.1 Avadel Pharmaceuticals
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 F. Hoffmann-La Roche
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Pfizer
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Argenx
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
2. INTRODUCTION
2.1 Overview of Myasthenia Gravis
2.1.1 Myasthenia Gravis Statistics
2.1.2 Myasthenia Gravis Classification
2.1.3 Symptoms of Myasthenia Gravis
2.1.4 Causes of Myasthenia Gravis
2.1.5 Treatment Types for Myasthenia Gravis
3. GLOBAL MARKET ANALYSIS
3.1 Global Myasthenia Gravis Market Analysis
3.1.1 Global Myasthenia Gravis Drugs Market by Value
3.1.2 Global Myasthenia Gravis Market by Therapy
Anticholinesterase inhibitors
Immunosuppressants
Intravenous Immune Globulins
3.1.3 Global Myasthenia Gravis Market by Cases
Peripheral muscles
Ocular Muscles
Bulbar Muscles
3.1.4 Global Myasthenia Gravis Cases by Severity
4. REGIONAL ANALYSIS
4.1 The US Myasthenia Gravis Market Analysis
4.1.1 The US Myasthenia Gravis Market by Total Patient Volume
4.1.2 The US Myasthenia Gravis Market by 2nd Line Patient Volume
4.1.3 The US Myasthenia Gravis Market by 3rd Line Severe Chronic Refractory Patient Volume
4.1.4 The US Myasthenia Gravis Market by Crisis Patient Volume
5. MARKET DYNAMICS
5.1 Growth Drivers
5.1.1 Rising Prevalence of Disease
5.1.2 Technological Advancements
5.1.3 Rising Geriatric Population
5.2 Challenges
5.2.1 Competition from Off-Label Drugs
5.2.2 Limited Availability of FDA Approved Drugs
5.2.3 High Cost
5.3 Market Trends
5.3.1 Emergence of New Entrants
5.3.2 Growing Number of Mergers and Acquisitions
5.3.3 Approval of Novel Monoclonal Antibodies
6. COMPETITIVE LANDSCAPE
6.1 The US Myasthenia Gravis Market Players by Product Comparison
7. COMPANY PROFILING
7.1 Avadel Pharmaceuticals
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 F. Hoffmann-La Roche
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Pfizer
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Argenx
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Myasthenia Gravis Statistics
Figure 2: Myasthenia Gravis Classification
Figure 3: Treatment Types for Myasthenia Gravis
Figure 4: Global Myasthenia Gravis Drugs Market by Value; 2016-2021 (US$ Million)
Figure 5: Global Myasthenia Gravis Market by Therapy; 2016
Figure 6: Global Myasthenia Gravis Market by Cases; 2016
Figure 7: Global Myasthenia Gravis Case by Severity; 2016
Figure 8: The US Myasthenia Gravis Market by Total Patient Volume; 2017-2021E (Thousand)
Figure 9: The US Myasthenia Gravis Market by 2nd Line Patient Volume; 2017-2021E (Thousand)
Figure 10: The US Myasthenia Gravis Market by 3rd Line Severe Chronic Refractory Patient Volume; 2017-2021E (Thousand)
Figure 11: The US Myasthenia Gravis Market by Crisis Patient Volume; 2017-2021E (Thousand)
Figure 12: Global Population Aged 65 Years and Above; 2015-2050 (Millions)
Figure 13: Avadel Pharmaceuticals Revenue; 2015-2016 (US$ Million)
Figure 14: F. Hoffmann-La Roche Sales; 2015-2016 (US$ Billion)
Figure 15: F. Hoffmann-La Roche Sales by Segments; 2016
Figure 16: Pfizer Revenue; 2014-2016 (US$ Billion)
Figure 17: Medrol Revenue; 2014-2016 (US$ Million)
Figure 18: Pfizer Revenue by Segments; 2016
Figure 19: Pfizer Revenue by Geography; 2016
Figure 20: Argenx Revenue; 2015-2016 (US$ Million)
Figure 1: Myasthenia Gravis Statistics
Figure 2: Myasthenia Gravis Classification
Figure 3: Treatment Types for Myasthenia Gravis
Figure 4: Global Myasthenia Gravis Drugs Market by Value; 2016-2021 (US$ Million)
Figure 5: Global Myasthenia Gravis Market by Therapy; 2016
Figure 6: Global Myasthenia Gravis Market by Cases; 2016
Figure 7: Global Myasthenia Gravis Case by Severity; 2016
Figure 8: The US Myasthenia Gravis Market by Total Patient Volume; 2017-2021E (Thousand)
Figure 9: The US Myasthenia Gravis Market by 2nd Line Patient Volume; 2017-2021E (Thousand)
Figure 10: The US Myasthenia Gravis Market by 3rd Line Severe Chronic Refractory Patient Volume; 2017-2021E (Thousand)
Figure 11: The US Myasthenia Gravis Market by Crisis Patient Volume; 2017-2021E (Thousand)
Figure 12: Global Population Aged 65 Years and Above; 2015-2050 (Millions)
Figure 13: Avadel Pharmaceuticals Revenue; 2015-2016 (US$ Million)
Figure 14: F. Hoffmann-La Roche Sales; 2015-2016 (US$ Billion)
Figure 15: F. Hoffmann-La Roche Sales by Segments; 2016
Figure 16: Pfizer Revenue; 2014-2016 (US$ Billion)
Figure 17: Medrol Revenue; 2014-2016 (US$ Million)
Figure 18: Pfizer Revenue by Segments; 2016
Figure 19: Pfizer Revenue by Geography; 2016
Figure 20: Argenx Revenue; 2015-2016 (US$ Million)
LIST OF TABLES
Table 1: Plasmapheresis, Immunoadsorption and, IVIg Treatments Difference
Table 2: Off-Label Options for Myasthenia Gravis
Table 3: Medications for Myasthenia Gravis
Table 4: The US Myasthenia Gravis Market Players by Product Comparison
Table 1: Plasmapheresis, Immunoadsorption and, IVIg Treatments Difference
Table 2: Off-Label Options for Myasthenia Gravis
Table 3: Medications for Myasthenia Gravis
Table 4: The US Myasthenia Gravis Market Players by Product Comparison
